At the initiation of our studies, we sought to use pharmacological, genetic and unbiast screening approaches to determine the molecular mechanisms for SGLT2 inhibitor, EMPA, on improved cardiac function and remodeling after MI. This evidence concerns the gene SLC5A2 and myocardial infarction.